These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11951792)

  • 21. Drug-eluting stents: the panacea for restenosis?
    Lim MC
    Singapore Med J; 2004 Jul; 45(7):300-2. PubMed ID: 15221043
    [No Abstract]   [Full Text] [Related]  

  • 22. [When are drug-eluting stents effective? A critical analysis of the presently available data].
    Silber S
    Z Kardiol; 2004 Sep; 93(9):649-63. PubMed ID: 15365732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus-eluting stents vs brachytherapy for restenosis.
    Alfonso F; Sabate M
    JAMA; 2006 Oct; 296(15):1837-8; author reply 1838. PubMed ID: 17047209
    [No Abstract]   [Full Text] [Related]  

  • 24. [Efficacy of sirolimus-eluting stent implantation in diabetic patients with very small vessels (< or = 2.25 mm). Insights from the DIABETES trial].
    Jiménez-Quevedo P; Sabaté M; Angiolillo DJ; Alfonso F; Hernández-Antolín R; Gómez-Hospital JA; Sanmartín M; Bañuelos C; Moreno R; Escaned J; Fernández C; Costa MA; Fernández-Avilés F; Macaya C
    Rev Esp Cardiol; 2006 Oct; 59(10):1000-7. PubMed ID: 17125709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-eluting stents: preventing restenosis.
    Slavin L; Chhabra A; Tobis JM
    Cardiol Rev; 2007; 15(1):1-12. PubMed ID: 17172878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-eluting stents: immediate and long-term results.
    Korovesis S; Karvouni E; Giazitzoglou E; Katritsis D
    Hellenic J Cardiol; 2005; 46(5):330-5. PubMed ID: 16295941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 3-year follow-up of the SISR (Sirolimus-Eluting Stents Versus Vascular Brachytherapy for In-Stent Restenosis) trial.
    Holmes DR; Teirstein PS; Satler L; Sketch MH; Popma JJ; Mauri L; Wang HP; Schleckser PA; Cohen SA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):439-48. PubMed ID: 19463342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents.
    Mauri L; O'Malley AJ; Popma JJ; Moses JW; Leon MB; Holmes DR; Teirstein PS; Cutlip DE; Donahoe D; Kuntz RE
    Am J Cardiol; 2005 May; 95(10):1140-5. PubMed ID: 15877983
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-eluting stents.
    Chieffo A; Colombo A
    Minerva Cardioangiol; 2002 Oct; 50(5):419-29. PubMed ID: 12384624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents.
    Albiero R; Nishida T; Adamian M; Amato A; Vaghetti M; Corvaja N; Di Mario C; Colombo A
    Circulation; 2000 May; 101(21):2454-7. PubMed ID: 10831516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis.
    Doggrell SA
    Expert Opin Pharmacother; 2004 Nov; 5(11):2209-20. PubMed ID: 15500367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients.
    Regar E; Lemos PA; Saia F; Degertekin M; Tanabe K; Lee CH; Arampatzis CA; Hoye A; Sianos G; de Feyter P; van der Giessen WJ; Smits PC; van Domburg RT; Serruys PW
    Am J Cardiol; 2004 May; 93(10):1271-5. PubMed ID: 15135702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which parameter should be chosen as primary endpoint for randomized drug-eluting stent studies?
    Silber S
    J Interv Cardiol; 2004 Dec; 17(6):375-85. PubMed ID: 15546289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).
    Schofer J; Schlüter M; Gershlick AH; Wijns W; Garcia E; Schampaert E; Breithardt G;
    Lancet; 2003 Oct; 362(9390):1093-9. PubMed ID: 14550694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Stents in interventional cardiology].
    Grinius V; Navickas R; Unikas R
    Medicina (Kaunas); 2007; 43(3):183-9. PubMed ID: 17413246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-eluting stents.
    García-García HM; Vaina S; Tsuchida K; Serruys PW
    Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intracoronary radiation therapy in controlled and open clinical trials with afterloading systems and "hot" balloon catheters. Analysis of 6,692 patients].
    Silber S
    Herz; 2002 Feb; 27(1):30-55. PubMed ID: 11951794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Drug-eluting stents do they make the difference? ].
    Presbitero P; Asioli M
    Minerva Cardioangiol; 2002 Oct; 50(5):431-42. PubMed ID: 12384625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis.
    Kuchulakanti P; Waksman R
    Drugs; 2004; 64(21):2379-88. PubMed ID: 15481997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.